发明授权
- 专利标题： Method for determining risk of relapse of breast cancer following tamoxifen adjuvant therapy
- 专利标题（中）： 替莫昔芬辅助治疗后确定乳腺癌复发风险的方法
-
申请号： US10517741申请日： 2003-10-01
-
公开(公告)号： US08101359B2公开(公告)日： 2012-01-24
- 发明人: John Foekens , Nadia Harbeck , Thomas Koenig , Sabine Maier , John W. Martens , Fabian Model , Inko Nimmrich , Tamas Rujan , Armin Schmitt , Manfred Schmitt , Maxime P. Look , Almuth Marx , Heinz Hoefler
- 申请人： John Foekens , Nadia Harbeck , Thomas Koenig , Sabine Maier , John W. Martens , Fabian Model , Inko Nimmrich , Tamas Rujan , Armin Schmitt , Manfred Schmitt , Maxime P. Look , Almuth Marx , Heinz Hoefler
- 申请人地址： DE Berlin
- 专利权人： Epigenomics AG
- 当前专利权人： Epigenomics AG
- 当前专利权人地址： DE Berlin
- 代理机构： DLA Piper LLP (US)
- 优先权： DE10245779 20021001; DE10300096 20030107; DE10317955 20030417
- 国际申请： PCT/EP03/10881 WO 20031001
- 国际公布： WO2004/035803 WO 20040429
- 主分类号： C12Q1/68
- IPC分类号： C12Q1/68 ; C12P19/34 ; C07H21/02 ; C07H21/04
摘要：
The present invention relates to modified and genomic sequences, to oligonucleotides and/or PNA-oligomers for detecting the cytosine methylation state of genomic DNA, as well as to a method for predicting the response of a subject with a cell proliferative disorder of the breast tissues, to endocrine treatment.
公开/授权文献
信息查询
